Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab - Summary - MDSpire

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

  • By

  • Jens Rathmann

  • Hiba Kadhem

  • Mårten Segelmark

  • David Jayne

  • Aladdin J. Mohammad

  • June 16, 2026

  • 0 min

Share

Objective:

Consider adding the significance of studying HG in RTX-treated AAV patients.

Key Findings:
  • Include the significance of the incidence rate.
Interpretation:

Elaborate on the implications of HG not being associated with severe infections.

Limitations:
  • Mention potential biases in retrospective studies more explicitly.
Conclusion:

Emphasize the clinical implications of close IgG monitoring.

Original Source(s)

Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab

  • by Jens Rathmann, Hiba Kadhem, Mårten Segelmark, David Jayne, Aladdin J. Mohammad

  • June 16, 2026

Related Content

Normal serum uric acid gout: a neglected and challenging condition

Fibromyalgia in cancer patients: a systematic review and clinical implications for integrated care

AKT-mediated phosphorylation of ZDHHC5 promotes NOD1 palmitoylation and innate immune signaling